Open AccessPharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy
Author(s) -
Tim R. Cressey,
Gonzague Jourdain,
Boonsong Rawangban,
Supang Varadisai,
Rucha Kongpanichkul,
Prapan Sabsag,
Prapap Yuthavisuthi,
Somnuk Chirayus,
Nicole NgoGiangHuong,
Nipunporn Voramongkol,
Somsak Pattarakulwanich,
Marc Lallemant
Publication year - 2010
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e32833ce57d
Subject(s) - lopinavir/ritonavir , lopinavir , medicine , zidovudine , ritonavir , pharmacokinetics , cmin , cmax , pregnancy , viral load , confidence interval , area under the curve , gestation , pharmacology , immunology , human immunodeficiency virus (hiv) , viral disease , antiretroviral therapy , biology , genetics
To evaluate the pharmacokinetics and HIV viral load response following initiation during the third trimester of pregnancy of zidovudine plus standard-dose lopinavir boosted with ritonavir (LPV/r), twice daily, until delivery for the prevention of mother-to-child transmission of HIV.